Genetic clues link immune responses to severe COVID-19 in children

Overview

The following summary mirrors a Nature publication about a pediatric COVID-19 study, highlighting how gene expression in blood reveals immune mechanisms linked to severe disease and potential cross-disease defence patterns.

• Stronger neutrophil responses and interferon-gamma signaling are associated with severe respiratory infections.
• Thousands of genes show altered activity in severe cases, with over 5,000 genes affected across severe infections.
• 82 genes may help distinguish severe COVID-19 from mild or asymptomatic cases.
• Seven immune cell types show shared activity patterns across COVID-19, RSV, and pulmonary tuberculosis, suggesting common defence mechanisms.

Overview

According to a Nature-published study, blood gene expression profiles from 333 South African children were analyzed to understand why a subset develop severe COVID-19. The cohort consisted of 127 healthy children, 71 with mild or asymptomatic COVID-19, 41 hospitalized with severe COVID-19, 47 with RSV, and 47 with pulmonary tuberculosis. All children had similar genetic backgrounds, and analyses were adjusted for age. The researchers identified thousands of genes whose activity differed in severe respiratory infections compared with healthy controls, with more than 5,000 genes altered in severe cases. The findings highlight immune pathways, including neutrophil-driven responses and interferon-gamma signaling, that characterize severe disease, while also revealing differences in circulating immune cell types: higher macrophage proportions and lower T cells in severe infections.

Study design and participants

The study focused on children exposed to a single respiratory infection to reduce confounding factors. By comparing severe cases to healthy controls and other infections such as RSV and TB, the team mapped gene expression changes across conditions. Age was used as a covariate to ensure the observed differences were not simply age-related.

Key findings

1) Immune responses in severe respiratory infections showed a distinctive gene expression signature. Neutrophil pathways were upregulated, aligning with the body’s rapid defense against pathogens. Interferon-gamma signaling, a key coordinator of immune responses, was switched on in severe infections. These changes reflect robust immune activation associated with disease severity.

2) Immune cell composition in blood differed with disease severity. Children with severe infections had higher proportions of macrophages and lower proportions of T cells, suggesting a shift from coordinated adaptive responses toward innate immunity in more severe disease. These patterns were not observed in mild or asymptomatic COVID-19 or in healthy children.

Shared and unique immune patterns

The researchers identified seven immune cell types showing similar activity patterns across COVID-19, RSV, and TB, implying a common set of host defence mechanisms when the lung is severely affected. At the same time, other gene expression patterns appeared to be infection-specific, underscoring biological differences between diseases and the potential to tailor therapies to the infection type.

Implications for diagnosis and therapy

82 genes were highlighted as potential markers to distinguish severe from mild COVID-19 in children, raising the possibility of using gene expression signatures to identify those at greatest risk of severe disease. While promising, the authors caution that these findings are at an discovery stage and require validation in larger, independent cohorts before clinical use. The study also points to potential targets for future research and therapy development, particularly around immune pathways implicated in severity and cross-d disease defence mechanisms.

Limitations and next steps

The authors emphasize that this work represents initial discovery rather than a clinical breakthrough. Prospective studies with larger, diverse populations are needed to confirm predictive value and to test gene-based risk stratification tools in real-world settings. Further research may also examine how these gene expression patterns respond to therapies and vaccines, and whether similar signatures are present in other pediatric populations.

Original publisher: Nature